Skip to main content
. 2013 Apr 30;9(1):9–13. doi: 10.46582/jsrm.0901003

Figure 2.

Figure 2

A retrospective analysis of the survival time in patients with stage IV pancreatic cancer who received hyperthermia and/or AIET. All our 63 patients received hyperthermia and chemotherapy. After receiving informed consent from the patients, 41 out of 63 patients received NK cell-based AIET and some patients also received T cell- and DC-based AIET. The survival time of patients who received AIET was compared with those of our 22 patients receiving hyperthermia without AIET and the 338 patients receiving conventional treatment, mostly chemotherapy alone in a data of Survival statistics of Japanese association of Clinical Cancer Centers by Kaplan-Meier method of KapWeb [28] from 18 core medical centers for cancer in Japan in 2004.